Q-Line Biotech (NSE:QLINE) Total Operating Expense: ₹627 Mil (TTM As of Mar. 2025)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Total Operating Expense?

Q-Line Biotech NSE:QLINE -5.15% 12 Total Operating Expense is ₹627 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's Total Operating Expense for the six months ended in Mar. 2025 was ₹627 Mil. Q-Line Biotech's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₹627 Mil.

Q-Line Biotech Total Operating Expense Related Terms

Q-Line Biotech Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Total Operating Expense Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Total Operating Expense
458.24 483.98 626.71

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Total Operating Expense 458.24 483.98 626.71
NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₹627 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹627 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Total Operating Expense of ₹627 Mil as of Mar. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Total Operating Expense too high?
Q-Line Biotech's current Total Operating Expense is ₹627 Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Total Operating Expense compare to ABT and SYK?
Q-Line Biotech's Total Operating Expense of ₹627 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Total Operating Expense is ₹627 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Total Operating Expense of ₹627 Mil. The current Total Operating Expense is ₹627 Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Total Operating Expense is ₹627 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price